We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi pasteur, the vaccines unit Sanofi Aventis SA, said Monday that it will license a vaccine booster from Japanese drug maker Eisai Co. Financial details of the agreement were not disclosed. Sanofi will license Eisai's vaccine booster E6020 in the development of new vaccines.
Pharmacies in the United Arab Emirates (UAE) are reportedly selling
drugs without warning about potentially dangerous side effects after the Health Ministry recently moved to reduce drug prices in the country.
The Brazilian pharmaceutical sector will benefit from the government's new tax incentives to exporters of hi-tech products, worth BRL3.3bn (US$1.47bn).
India's new liberalised drug-pricing regime, which is being announced this month, will cause drug prices to increase in the long term, although they are expected to remain unchanged in the first year, according to a recent government report.
IVAX said it filed its Abbreviated New Drug Application (ANDA) for budesonide inhalation suspension with the US Food and Drug Administration in late 2004.
Shares of OSI Pharmaceuticals Inc. fell more than 8% on Tuesday after research partner Genentech said that preliminary Phase II clinical results had shown OSI's drug Tarceva not to be very effective in battling kidney cancer.
Generex Biotechnology Corporation (Nasdaq: GNBT -- News) announced today that it has received, over the past two weeks, an aggregate of $6.4 million as a result of the exercise by existing Company investors of previously issued warrants.
Chromos Molecular Systems Inc. (TSX:CHR) announced today that it has entered into a definitive agreement under which it will acquire Targeted Molecules Corporation ("TMC"), a privately held San Diego based biotechnology company focused on the research and development of two antibody product candidates for treatment of multiple sclerosis (MS) and acute thrombosis.
Beijing Med-Pharm Corporation (BJGP.PK) and pSivida Limited (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) today announced that they have signed a licensing agreement for the clinical development, marketing, and distribution of pSivida's lead product, BrachySil(TM), in the People's Republic of China. Under the terms of the license, pSivida will manufacture BrachySil(TM) and Beijing Med-Pharm will be responsible for clinical development, securing regulatory approval, marketing, and distribution in China.